CRSP
Price
$54.82
Change
+$3.63 (+7.09%)
Updated
Jul 8 closing price
Capitalization
4.73B
33 days until earnings call
PGEN
Price
$1.70
Change
+$0.11 (+6.92%)
Updated
Jul 8 closing price
Capitalization
501.81M
33 days until earnings call
Interact to see
Advertisement

CRSP vs PGEN

Header iconCRSP vs PGEN Comparison
Open Charts CRSP vs PGENBanner chart's image
CRISPR Therapeutics AG
Price$54.82
Change+$3.63 (+7.09%)
Volume$3.78M
Capitalization4.73B
Precigen
Price$1.70
Change+$0.11 (+6.92%)
Volume$1.75M
Capitalization501.81M
CRSP vs PGEN Comparison Chart in %
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. PGEN commentary
Jul 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a StrongBuy and PGEN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 09, 2025
Stock price -- (CRSP: $54.82 vs. PGEN: $1.70)
Brand notoriety: CRSP and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 139% vs. PGEN: 95%
Market capitalization -- CRSP: $4.73B vs. PGEN: $501.81M
CRSP [@Biotechnology] is valued at $4.73B. PGEN’s [@Biotechnology] market capitalization is $501.81M. The market cap for tickers in the [@Biotechnology] industry ranges from $309.49B to $0. The average market capitalization across the [@Biotechnology] industry is $2.38B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, both CRSP and PGEN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 5 TA indicator(s) are bullish while PGEN’s TA Score has 6 bullish TA indicator(s).

  • CRSP’s TA Score: 5 bullish, 4 bearish.
  • PGEN’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PGEN is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +13.01% price change this week, while PGEN (@Biotechnology) price change was +17.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.39%. For the same industry, the average monthly price growth was +14.41%, and the average quarterly price growth was +12.94%.

Reported Earning Dates

CRSP is expected to report earnings on Oct 29, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+9.39% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.73B) has a higher market cap than PGEN($502M). PGEN YTD gains are higher at: 51.786 vs. CRSP (39.278). PGEN has higher annual earnings (EBITDA): -154.85M vs. CRSP (-455.24M). CRSP has more cash in the bank: 1.86B vs. PGEN (80.2M). PGEN has less debt than CRSP: PGEN (5.42M) vs CRSP (219M). CRSP has higher revenues than PGEN: CRSP (35M) vs PGEN (4.2M).
CRSPPGENCRSP / PGEN
Capitalization4.73B502M943%
EBITDA-455.24M-154.85M294%
Gain YTD39.27851.78676%
P/E RatioN/AN/A-
Revenue35M4.2M833%
Total Cash1.86B80.2M2,313%
Total Debt219M5.42M4,043%
FUNDAMENTALS RATINGS
CRSP vs PGEN: Fundamental Ratings
CRSP
PGEN
OUTLOOK RATING
1..100
3124
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
94100
PRICE GROWTH RATING
1..100
3943
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CRSP's Valuation (67) in the Biotechnology industry is in the same range as PGEN (71) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's SMR Rating (94) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's Price Growth Rating (39) in the Biotechnology industry is in the same range as PGEN (43) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

CRSP's P/E Growth Rating (81) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that CRSP’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPPGEN
RSI
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
63%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 6 days ago
84%
Declines
ODDS (%)
Bearish Trend 27 days ago
84%
Bearish Trend 12 days ago
85%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FBTIX29.17N/A
N/A
Fidelity Advisor Biotechnology I
LONGX14.61N/A
N/A
Longboard I
RICIX11.17N/A
N/A
T. Rowe Price Intl Disciplined Eq I
ASVGX10.12N/A
N/A
American Century Small Cap Value R5
RPNLX13.32N/A
N/A
RiverPark/Next Century Lg Gr Inst